These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17443030)

  • 1. A health-economic evaluation of aspirin: primary prevention and cardiovascular disease.
    Sakai T; Saku K
    Intern Med; 2007; 46(8):431-3. PubMed ID: 17443030
    [No Abstract]   [Full Text] [Related]  

  • 2. Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
    Noubiap JJ; Nansseu JR
    Vasc Health Risk Manag; 2015; 11():503-6. PubMed ID: 26345154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention.
    Annemans L; Wittrup-Jensen K; Bueno H
    J Med Econ; 2010; 13(3):418-27. PubMed ID: 20632895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
    Tsutani K; Igarashi A; Fujikawa K; Evers T; Kubin M; Lamotte M; Annemans L
    Intern Med; 2007; 46(4):157-62. PubMed ID: 17301509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polish forum for prevention guidelines on cardiovascular risk assessment].
    Podolec P; Kopeć G; Pajak A; Undas A; Kozek E; Tykarski A; Naruszewicz M; Stańczyk J; Opala G; Godycki-Cwirko M; Rynkiewicz A; Torbicki A; Musiał J
    Kardiol Pol; 2007 Jan; 65(1):100-4. PubMed ID: 17295170
    [No Abstract]   [Full Text] [Related]  

  • 6. Common interests and common goals: achieving greater progress in preventive health through strategic collaborations.
    Vance RB
    CA Cancer J Clin; 2004; 54(4):188-9. PubMed ID: 15253916
    [No Abstract]   [Full Text] [Related]  

  • 7. What Do the Guidelines Really Say About Aspirin?
    Millard MA; Hernandez-Vila EA
    Tex Heart Inst J; 2018 Aug; 45(4):228-230. PubMed ID: 30374231
    [No Abstract]   [Full Text] [Related]  

  • 8. Aspirin for primary cardiovascular disease prevention: time to re-evaluate guidelines?
    Barmanray R; Hamblin PS
    Intern Med J; 2019 Jan; 49(1):133-134. PubMed ID: 30680892
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
    Matthys F; De Backer T; De Backer G; Stichele RV
    Eur J Prev Cardiol; 2014 Mar; 21(3):354-65. PubMed ID: 23610452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential economic impact of increasing low dose aspirin usage on CVD in the US.
    Manson SC; Benedict A; Pan F; Wittrup-Jensen KU; Fendrick AM
    Curr Med Res Opin; 2010 Oct; 26(10):2365-73. PubMed ID: 20738228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
    Neyt M; De Laet C; Van Brabandt H; Franco O; Ramaekers D
    Acta Cardiol; 2009 Feb; 64(1):1-10. PubMed ID: 19317290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On reducing cardiovascular disease to a rarity: clinical strategies and their cost-effectiveness.
    Lewis B; Watts GF; Sullivan DR
    Heart Lung Circ; 2010 Apr; 19(4):225-7. PubMed ID: 20149730
    [No Abstract]   [Full Text] [Related]  

  • 13. Aspirin for primary prevention: do potential benefits outweigh the risks?
    Shakib S
    Intern Med J; 2009 Jun; 39(6):401-7. PubMed ID: 19580619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events.
    Rodondi N; Bauer DC
    Am J Med; 2004 Oct; 117(7):528-30. PubMed ID: 15464713
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of public health demonstration programs: the effectiveness and cost-effectiveness of WISEWOMAN.
    Finkelstein EA; Wittenborn JS; Farris RP
    J Womens Health (Larchmt); 2004 Jun; 13(5):625-33. PubMed ID: 15257854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin for primary prevention of cardiovascular disease in women: does sex matter?
    Hung J
    Med J Aust; 2006 Mar; 184(6):260-1. PubMed ID: 16548826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.
    Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
    Cardiovasc Ther; 2013 Feb; 31(1):45-52. PubMed ID: 21884025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin for primary prevention of cardiovascular disease?
    Drug Ther Bull; 2009 Nov; 47(11):122-5. PubMed ID: 19887685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
    Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
    Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of cardiovascular risk factor information in practice databases: making the best of patient data.
    Marshall T
    Br J Gen Pract; 2006 Aug; 56(529):600-5. PubMed ID: 16882378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.